HALO

Halozyme Therapeutics Inc

127.60

Oct 27 • 6:12 AM ET -0.41 (-0.32%)

Healthcare Biotechnology USA Large NASD

Peers: LGND RPRX ASND WST ARGX ALKS EXEL BMRN CORT PCRX

| Held by: IJH VTI VB XBI VBK VXF FBT IBB MDY DFAS

Index	-
Market Cap	14.48B
Enterprise Value	16.40B
Income	413.60M
Sales	1.66B
Book/sh	1.26
Cash/sh	2.04
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	423
IPO	Mar 12, 2004

P/E	38.12
Forward P/E	12.26
PEG	0.29
P/S	8.70
P/B	101.38
P/C	62.69
P/FCF	17.96
EV/EBITDA	15.48
EV/Sales	9.86
Quick Ratio	2.31
Current Ratio	2.71
Debt/Eq	14.96
LT Debt/Eq	13.50
Option/Short	Yes / Yes

EPS (ttm)	3.35
EPS next Y	10.41
EPS next Q	2.30
EPS this Y	107.59%
EPS next Y	20.81%
EPS next 5Y	42.80%
EPS past 3/5Y	21.17% 22.89%
Sales past 3/5Y	28.38% 39.16%
EPS Y/Y TTM	-21.44%
Sales Y/Y TTM	41.15%
EPS Q/Q	42.59%
Sales Q/Q	47.67%
Earnings	Nov 05 AMC
EPS/Sales Surpr.	27.58% 19.57%

Insider Own	1.08%
Insider Trans	-20.70%
Inst Own	111.56%
Inst Trans	1.06%
ROA	17.86%
ROE	173.67%
ROIC	19.87%
Gross Margin	76.40%
Oper. Margin	56.77%
Profit Margin	24.86%
SMA20	9.31%
SMA50	13.71%
SMA200	54.68%
Trades

Shs Outstand	114.04M
Shs Float	112.27M
Short Float	12.16%
Short Ratio	5.95
Short Interest	13.65M
52W High	128.11 -0.40%
52W Low	61.22 108.41%
Volatility	2.06% 2.86%
ATR (14)	3.15
RSI (14)	75.19
Beta	0.94
Rel Volume	0.00
Avg Volume	2.30M
Volume	29

Perf Week	2.60%
Perf Month	13.03%
Perf Quarter	53.22%
Perf Half Y	99.81%
Perf YTD	89.60%
Perf Year	93.77%
Perf 3Y	282.26%
Perf 5Y	240.99%
Perf 10Y	1333.71%
Recom	1.73
Target Price	108.78
Prev Close	128.01
Price	127.60
Change %	-0.32%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-07-26	Upgrade	Leerink Partners	Market Perform → Outperform	$110
Dec-04-25	Downgrade	Goldman	Neutral → Sell	$56
Oct-14-25	Upgrade	Leerink Partners	Underperform → Market Perform	$70
Aug-06-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$75
Jul-10-25	Resumed	Goldman	Neutral	$55
May-14-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$62
May-13-25	Downgrade	Leerink Partners	Market Perform → Underperform	$47
Oct-07-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$58 → $62
Sep-19-24	Downgrade	JP Morgan	Overweight → Neutral	$52 → $57
Jun-07-24	Downgrade	Piper Sandler	Overweight → Neutral	$48 → $51
Feb-29-24	Initiated	TD Cowen	Outperform	$54
Jul-24-23	Initiated	H.C. Wainwright	Buy	$61
Jul-24-23	Downgrade	Goldman	Buy → Neutral	$43 → $45
May-10-23	Upgrade	Piper Sandler	Neutral → Overweight	$46
Mar-27-23	Resumed	Berenberg	Buy	$58
Mar-16-23	Downgrade	SVB Securities	Outperform → Market Perform	$42
Dec-21-22	Resumed	Morgan Stanley	Overweight	$53 → $65
Nov-28-22	Initiated	Wells Fargo	Overweight	$65
Sep-09-22	Initiated	Morgan Stanley	Overweight	$50
May-23-22	Initiated	SVB Leerink	Outperform	$52

Show Previous Ratings

Oct-23-26 08:04AM	How Halozyme, Up 80% This Year, Is Rivaling Merck And Hitting New Highs (Investor's Business Daily)
Oct-22-26 08:30AM	Halozyme to Report Third Quarter 2026 Financial and Operating Results (PR Newswire)
Oct-14-26 04:28PM	Top Research Reports for Mastercard, AstraZeneca & Sandisk (Zacks) +6.57%
Oct-07-26 11:21AM	Halozyme stock rises after winning injunction against Merck (Investing.com)
08:30AM	Halozyme Wins Injunction Stopping Manufacture and Sale of Merck's Keytruda SC in Multiple European Markets (PR Newswire)
04:05PM	Loading…
Oct-06-26 04:05PM	Halozyme Announces Expansion of Global Collaboration and License Agreement with argenx to Support the Development of Subcutaneous Formulations for Two Additional Exclusive Targets Using its ENHANZE Technology (PR Newswire)
Sep-30-26 04:05PM	Halozyme Announces Appointment of Jim Daly to its Board of Directors (PR Newswire)
Sep-28-26 03:13PM	Eli Lilly Upgraded, Intel Downgraded: Updated Rankings on Top Blue-Chip Stocks (InvestorPlace)
Sep-17-26 11:20PM	Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033 (PR Newswire)
Sep-16-26 04:30PM	Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033 (PR Newswire)
Sep-02-26 10:40AM	Halozyme Investor Conferences Put ENHANZE and Expanded Drug Delivery Portfolio in Focus (InvestorsHub)
08:30AM	Halozyme to Participate at Upcoming Investor Conferences (PR Newswire)
Aug-28-26 04:14PM	Tight Action In HALO Stock Sets Up Heavenly Gains (Investor's Business Daily)
Aug-18-26 04:01PM	Halozyme Appoints Dannielle Appelhans to its Board of Directors (PR Newswire)
Aug-07-26 11:06PM	Halozyme Therapeutics Inc (HALO) (Q2 2026) Earnings Call Highlights: Record Revenue and Royalty ... (GuruFocus.com) +20.24%
04:06PM	Loading…
04:06PM	Why Halozyme, An IBD 50 Stock, Just Hit A Record High In Bullish Volume (Investor's Business Daily)
01:55PM	These Two Biotech Stocks Hit Fresh 52-Week Highs Today NTRA Clocks Best Day In Nearly 20 Months (Stocktwits)
Aug-06-26 04:08PM	Halozyme Therapeutics: Q2 Earnings Snapshot (Associated Press)
04:01PM	HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE (PR Newswire)
Jul-29-26 01:56PM	This Medical Technology Stock Claws Back To A Buy Zone (Investor's Business Daily)
Jul-23-26 08:30AM	Halozyme to Report Second Quarter 2026 Financial and Operating Results (PR Newswire)
Jul-21-26 05:31AM	Halozyme and Incyte sign licence agreement for INCA033989 formulations (Pharmaceutical Technology)
Jul-20-26 11:02AM	Halozyme Signs ENHANZE Collaboration with Incyte for Subcutaneous INCA033989 Development (InvestorsHub)
08:00AM	Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE Technology (PR Newswire)
Jun-30-26 04:02PM	Halozyme Appoints David Ramsay as President Drug Delivery (PR Newswire)
Jun-15-26 06:00AM	Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029 (PR Newswire)
May-28-26 04:27PM	JPMorgan says large-cap biotech is back as profits and pipelines fuel upside (Investing.com)
May-12-26 03:06AM	Halozyme Therapeutics Inc (HALO) Q1 2026 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com) +6.81%
May-11-26 04:11PM	Halozyme Therapeutics: Q1 Earnings Snapshot (Associated Press)
04:01PM	HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE (PR Newswire)
09:00AM	Loading…
May-07-26 09:00AM	Halozyme Announces Global Collaboration and License Agreement with GSK to Develop Subcutaneous Formulations of Multiple Promising Oncology Targets (PR Newswire)
May-06-26 08:00AM	Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon Technology (PR Newswire)
Apr-30-26 04:30PM	Halozyme to Report First Quarter 2026 Financial and Operating Results (PR Newswire)
08:00AM	Halozyme Appoints Darren Snellgrove as Chief Financial Officer (PR Newswire)
Apr-08-26 05:32AM	Halozyme and Vertex sign deal for Hypercon technology (Hospital Management)
Apr-07-26 08:00AM	Halozyme Announces Global Collaboration and License Agreement with Vertex Pharmaceuticals for Hypercon Technology (PR Newswire)
Mar-12-26 08:30AM	Halozyme Appoints David Ramsay as Interim Chief Financial Officer (PR Newswire)
Mar-06-26 08:00AM	U.S. FDA Approves TECVAYLI in Combination with DARZALEX FASPRO for Relapsed/Refractory Multiple Myeloma (PR Newswire)
Mar-01-26 04:27AM	Is Halozyme Therapeutics (HALO) a Buy Post Earnings? (Insider Monkey)
Feb-28-26 11:54AM	Halozyme Therapeutics, Inc. (HALO): A Bull Case Theory (Insider Monkey)
Feb-25-26 08:30AM	Halozyme to Participate in Upcoming Investor Conferences (PR Newswire)
Feb-24-26 11:05PM	2 Reasons to Like HALO (and 1 Not So Much) (StockStory)
Feb-19-26 09:25AM	Halozyme (HALO) Loses 9% on Weak Earnings (Insider Monkey)
Feb-18-26 01:06PM	Tech Stocks Rebound, Crude Rallies Above $64 On Iran Tensions: What's Moving Markets Wednesday? (Benzinga) -9.01%
11:17AM	Halozyme's Q4 Earnings Miss, Higher Royalties Drive Y/Y Revenues (Zacks)
12:01AM	Halozyme Therapeutics Inc (HALO) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Feb-17-26 07:43PM	Halozyme Therapeutics Q4 Earnings Call Highlights (MarketBeat)
06:30PM	Here's What Key Metrics Tell Us About Halozyme Therapeutics (HALO) Q4 Earnings (Zacks)
05:10PM	Halozyme Therapeutics (HALO) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:20PM	Halozyme Therapeutics (NASDAQ:HALO) Surprises With Q4 CY2025 Sales (StockStory)
04:19PM	Halozyme Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	HALOZYME REPORTS FULL YEAR 2025 RECORD REVENUE OF $1.4 BILLION AND REITERATES STRONG 2026 FINANCIAL GUIDANCE (PR Newswire)
Feb-16-26 09:50AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock (Zacks)
08:30AM	Here's How Much a $1000 Investment in Halozyme Therapeutics Made 10 Years Ago Would Be Worth Today (Zacks)
Feb-15-26 08:00AM	The biopharma company trying to simplify drug delivery for patients (Yahoo Finance Video)
Feb-13-26 09:15AM	Stay Ahead of the Game With Halozyme Therapeutics (HALO) Q4 Earnings: Wall Street's Insights on Key Metrics (Zacks)
Feb-11-26 10:00AM	Earnings Preview: BioMarin Pharmaceutical (BMRN) Q4 Earnings Expected to Decline (Zacks)
Feb-10-26 04:05PM	Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results (PR Newswire)
11:15AM	Biotech: Halozyme CEO explains what it looks for in M&A targets (Yahoo Finance Video)
10:00AM	Halozyme Therapeutics (HALO) to Report Q4 Results: Wall Street Expects Earnings Growth (Zacks)
Feb-05-26 09:57AM	This Medical Technology Leader Sees Growth Into The 2040s (Investor's Business Daily)
Feb-04-26 06:09PM	Silicon Motion Moves Higher On Rosy Outlook (Investor's Business Daily)
10:39AM	Google Stock: What The Buy Side Expects From Cloud Computing Business (Investor's Business Daily)
09:40AM	Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term (Zacks)
08:21AM	Stock Market Today: Dow Rises Ahead Of Jobs Data; AMD Plunges On Earnings (Live Coverage) (Investor's Business Daily)
Feb-03-26 04:57PM	Stock Market Today: Nasdaq Gets Hit Hardest As Techs Sink; Palantir Climbs After Earnings (Live Coverage) (Investor's Business Daily)
08:55AM	How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings (Zacks)
Feb-02-26 05:33PM	IBD Stock Of The Day Halozyme Eyes Two Buy Points; How It's 'Layering' Up For Future Growth (Investor's Business Daily)
12:10PM	Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Jan-31-26 08:00AM	5 Stocks To Watch Trade Near Buy Points; Three Are Data Center Plays (Investor's Business Daily)
Jan-30-26 09:50AM	Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term (Zacks)
08:30AM	If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now (Zacks)
Jan-29-26 01:25PM	H.C. Wainwright Sees Strength in Halozyme Therapeutics' ENHANZE Platform, Reiterates Buy Rating (Insider Monkey)
11:52AM	HALO Rises Nearly 4% on Strong 2025 Preliminary Data and 2026 Guidance (Zacks)
Jan-28-26 01:58PM	Halozyme Therapeutics Projects Sustained Growth Well Into 2040 (Benzinga)
12:02PM	Halozyme Therapeutics Raises 2026 Guidance After Hypercon, Surf Bio Deals Extend Platform Into 2040s (MarketBeat)
06:30AM	Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance (PR Newswire)
06:20AM	Halozyme buys a biotech startup; Cytokinetics launches heart drug (BioPharma Dive)
Jan-24-26 02:20PM	2 Under-the-Radar Biotech Stocks Set to Boom in 2026 (Motley Fool)
Jan-22-26 09:52PM	TD Cowen Notes Shifting Positive Sentiment for Halozyme (HALO) Ahead of Q4 Earnings, 2026 Guidance (Insider Monkey)
Jan-20-26 04:05PM	Halozyme to Host Investor Conference Call to Provide Updated Financial Guidance and Business Update (PR Newswire)
02:38PM	Halozyme (HALO) Boosted by ENHANZE Launches and Analyst Upgrade (Insider Monkey)
Jan-19-26 07:20PM	Halozyme Therapeutics: A 6.3 Rating and a Future Full of Uncertainty (Motley Fool)
Jan-18-26 10:36PM	Q3 Therapeutics Earnings: Halozyme Therapeutics (NASDAQ:HALO) Earns Top Marks (StockStory)
Jan-15-26 01:23PM	Oric Pharmaceuticals Stock Sees Healthy RS Rating Jump To 80 (Investor's Business Daily)
Jan-13-26 09:50AM	Halozyme Therapeutics (HALO) is a Top-Ranked Momentum Stock: Should You Buy? (Zacks)
Jan-12-26 09:40AM	Are Medical Stocks Lagging Ardelyx (ARDX) This Year? (Zacks)
Jan-09-26 11:40AM	HALO or AXSM: Which Is the Better Value Stock Right Now? (Zacks)
Jan-08-26 09:40AM	Are You a Value Investor? This 1 Stock Could Be the Perfect Pick (Zacks)
08:00AM	Halozyme Announces Global Collaboration and License Agreement with Takeda to Develop and Commercialize Vedolizumab with ENHANZE (PR Newswire)
Jan-07-26 11:04PM	Halozyme Therapeutics (HALO): Buy, Sell, or Hold Post Q3 Earnings? (StockStory)
11:25AM	Smorgasbord Of Buy Points Kicks Off 2026. Google, Nvidia On The Menu. (Investor's Business Daily)
Jan-06-26 09:38AM	CoreWeave initiated, Shopify downgraded: Wall Street's top analyst calls (The Fly)
Jan-05-26 07:00AM	Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE for Obesity (PR Newswire)
Jan-01-26 03:30PM	Halozyme Therapeutics (NASDAQ:HALO) Reports Bullish Q3 CY2025 (StockStory)
Dec-31-25 11:41AM	Here's What Analysts Think About Halozyme Therapeutics (HALO) (Insider Monkey)
Dec-23-25 12:46PM	Halozyme Therapeutics Stock Sees Relative Strength Rating (Investor's Business Daily)
03:53AM	J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant (Revised) (Zacks)
Dec-19-25 09:40AM	Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Torley Helen	PRESIDENT AND CEO	Oct 06 '26	Option Exercise	18.41	20,000	368,200	787,780	Oct 08 07:56 PM
Torley Helen	PRESIDENT AND CEO	Oct 07 '26	Option Exercise	18.41	20,000	368,200	787,780	Oct 08 07:56 PM
Torley Helen	PRESIDENT AND CEO	Oct 08 '26	Option Exercise	18.41	20,000	368,200	787,780	Oct 08 07:56 PM
Torley Helen	PRESIDENT AND CEO	Oct 07 '26	Sale	111.55	20,000	2,231,049	767,780	Oct 08 07:56 PM
Torley Helen	PRESIDENT AND CEO	Oct 06 '26	Sale	109.58	20,000	2,191,543	767,780	Oct 08 07:56 PM
Torley Helen	PRESIDENT AND CEO	Oct 08 '26	Sale	109.40	20,000	2,187,909	767,780	Oct 08 07:56 PM
Posard Matthew L.	Director	Oct 01 '26	Sale	108.54	5,230	567,661	53,609	Oct 02 04:38 PM
Posard Matthew L.	Director	Sep 16 '26	Sale	107.74	18,996	2,046,581	58,839	Sep 17 05:19 PM
MATTHEW POSARD	Director	Sep 16 '26	Proposed Sale	106.25	34,226	3,636,512		Sep 16 04:41 PM
Torley Helen	PRESIDENT AND CEO	Sep 09 '26	Option Exercise	18.41	20,000	368,200	787,780	Sep 11 08:35 PM
Torley Helen	PRESIDENT AND CEO	Sep 11 '26	Option Exercise	18.41	20,000	368,200	787,780	Sep 11 08:35 PM
Torley Helen	PRESIDENT AND CEO	Sep 10 '26	Option Exercise	18.41	20,000	368,200	787,780	Sep 11 08:35 PM
Torley Helen	PRESIDENT AND CEO	Sep 09 '26	Sale	107.43	20,000	2,148,536	767,780	Sep 11 08:35 PM
Torley Helen	PRESIDENT AND CEO	Sep 11 '26	Sale	107.24	20,000	2,144,856	767,780	Sep 11 08:35 PM
Torley Helen	PRESIDENT AND CEO	Sep 10 '26	Sale	107.17	20,000	2,143,319	767,780	Sep 11 08:35 PM
Torley Helen	PRESIDENT AND CEO	Aug 17 '26	Option Exercise	18.41	20,000	368,200	787,780	Aug 19 08:01 PM
Torley Helen	PRESIDENT AND CEO	Aug 18 '26	Option Exercise	18.41	20,000	368,200	787,780	Aug 19 08:01 PM
Torley Helen	PRESIDENT AND CEO	Aug 19 '26	Option Exercise	18.41	20,000	368,200	787,780	Aug 19 08:01 PM
Torley Helen	PRESIDENT AND CEO	Aug 19 '26	Sale	107.00	20,000	2,139,976	767,780	Aug 19 08:01 PM
Torley Helen	PRESIDENT AND CEO	Aug 18 '26	Sale	104.18	20,000	2,083,525	767,780	Aug 19 08:01 PM
Torley Helen	PRESIDENT AND CEO	Aug 17 '26	Sale	102.60	20,000	2,052,091	767,780	Aug 19 08:01 PM
Helen Torley	President, CEO, Director	Aug 17 '26	Proposed Sale	98.66	240,000	23,678,400		Aug 17 05:16 PM
CORTNEY A CAUDILL	Officer	Aug 11 '26	Proposed Sale	103.17	41,702	4,302,349		Aug 11 05:57 PM
Connaughton Bernadette	Director	Aug 10 '26	Sale	102.80	1,626	167,153	40,418	Aug 11 05:43 PM
BERNADETTE CONNAUGHTON	Director	Aug 10 '26	Proposed Sale	103.12	1,626	167,673		Aug 10 04:34 PM
Torley Helen	PRESIDENT AND CEO	Jul 08 '26	Option Exercise	12.07	1,923	23,211	769,703	Jul 09 05:19 PM
Torley Helen	PRESIDENT AND CEO	Jul 08 '26	Sale	79.77	1,923	153,391	767,780	Jul 09 05:19 PM
RAMSAY DAVID A	EVP, PRESIDENT, DRUG DELIVERY	Jun 30 '26	Option Exercise	0.00	10,000	0	10,000	Jul 02 04:45 PM
Connaughton Bernadette	Director	Jul 01 '26	Sale	76.71	1,625	124,651	42,044	Jul 02 04:42 PM
Krishnan Mahesh	Director	Jun 29 '26	Option Exercise	38.46	7,304	280,912	21,766	Jun 30 05:25 PM
Krishnan Mahesh	Director	Jun 29 '26	Sale	75.00	7,304	547,800	14,462	Jun 30 05:25 PM
MAHESH KRISHNAN	Director	Jun 29 '26	Proposed Sale	74.96	7,304	547,508		Jun 29 04:41 PM
Snyder Mark Howard	SVP, CHIEF LEGAL OFFICER	Jun 12 '26	Option Exercise	0.00	5,034	0	52,644	Jun 15 04:09 PM
Torley Helen	PRESIDENT AND CEO	Jun 01 '26	Option Exercise	12.07	20,000	241,400	787,780	Jun 03 08:06 PM
Torley Helen	PRESIDENT AND CEO	Jun 02 '26	Option Exercise	12.07	20,000	241,400	787,780	Jun 03 08:06 PM
Torley Helen	PRESIDENT AND CEO	Jun 03 '26	Option Exercise	12.07	10,000	120,700	777,780	Jun 03 08:06 PM
Torley Helen	PRESIDENT AND CEO	Jun 01 '26	Sale	67.58	20,000	1,351,610	767,780	Jun 03 08:06 PM
Torley Helen	PRESIDENT AND CEO	Jun 02 '26	Sale	66.39	20,000	1,327,745	767,780	Jun 03 08:06 PM
Torley Helen	PRESIDENT AND CEO	Jun 03 '26	Sale	69.07	10,000	690,653	767,780	Jun 03 08:06 PM
Connaughton Bernadette	Director	Jun 01 '26	Sale	66.21	1,625	107,591	43,669	Jun 02 05:20 PM
NICOLE LABROSSE	Former Officer	May 15 '26	Proposed Sale	67.12	14,700	986,592		May 15 04:13 PM
Torley Helen	PRESIDENT AND CEO	May 11 '26	Option Exercise	12.07	20,000	241,400	787,780	May 13 05:50 PM
Torley Helen	PRESIDENT AND CEO	May 12 '26	Option Exercise	12.07	20,000	241,400	787,780	May 13 05:50 PM
Torley Helen	PRESIDENT AND CEO	May 13 '26	Option Exercise	12.07	10,000	120,700	777,780	May 13 05:50 PM
Torley Helen	PRESIDENT AND CEO	May 12 '26	Sale	71.75	20,000	1,435,027	767,780	May 13 05:50 PM
Torley Helen	PRESIDENT AND CEO	May 11 '26	Sale	65.35	20,000	1,306,940	767,780	May 13 05:50 PM
Torley Helen	PRESIDENT AND CEO	May 13 '26	Sale	69.19	10,000	691,908	767,780	May 13 05:50 PM
Helen Torley	President, CEO, Director	May 11 '26	Proposed Sale	64.12	101,923	6,535,303		May 11 04:10 PM
Connaughton Bernadette	Director	May 01 '26	Sale	63.48	1,625	103,155	38,498	May 05 05:05 PM
BERNADETTE CONNAUGHTON	Director	May 01 '26	Proposed Sale	63.66	4,875	310,342		May 01 04:45 PM
Torley Helen	PRESIDENT AND CEO	Apr 06 '26	Option Exercise	12.07	10,000	120,700	777,780	Apr 07 05:13 PM
Torley Helen	PRESIDENT AND CEO	Apr 06 '26	Sale	63.50	10,000	634,982	767,780	Apr 07 05:13 PM
Torley Helen	PRESIDENT AND CEO	Apr 01 '26	Option Exercise	12.07	20,000	241,400	787,780	Apr 02 06:28 PM
Torley Helen	PRESIDENT AND CEO	Apr 02 '26	Option Exercise	12.07	20,000	241,400	787,780	Apr 02 06:28 PM
Torley Helen	PRESIDENT AND CEO	Apr 01 '26	Sale	65.38	20,000	1,307,516	767,780	Apr 02 06:28 PM
Torley Helen	PRESIDENT AND CEO	Apr 02 '26	Sale	64.24	20,000	1,284,721	767,780	Apr 02 06:28 PM
Caudill Cortney	SVP, CHIEF OPERATING OFFICER	Mar 09 '26	Option Exercise	33.51	20,000	670,200	34,366	Mar 10 07:18 PM
Caudill Cortney	SVP, CHIEF OPERATING OFFICER	Mar 10 '26	Option Exercise	33.51	1,546	51,806	15,912	Mar 10 07:18 PM
Caudill Cortney	SVP, CHIEF OPERATING OFFICER	Mar 09 '26	Sale	67.80	20,000	1,356,072	14,366	Mar 10 07:18 PM
Caudill Cortney	SVP, CHIEF OPERATING OFFICER	Mar 10 '26	Sale	67.64	8,857	599,087	7,055	Mar 10 07:18 PM
CORTNEY A CAUDILL	Officer	Mar 10 '26	Proposed Sale	67.64	8,857	599,088		Mar 10 04:05 PM
CORTNEY A CAUDILL	Officer	Mar 09 '26	Proposed Sale	67.80	20,000	1,356,062		Mar 09 04:18 PM
Torley Helen	PRESIDENT AND CEO	Mar 02 '26	Option Exercise	12.07	20,000	241,400	787,780	Mar 04 06:56 PM
Torley Helen	PRESIDENT AND CEO	Mar 03 '26	Option Exercise	12.07	20,000	241,400	787,780	Mar 04 06:56 PM
Torley Helen	PRESIDENT AND CEO	Mar 04 '26	Option Exercise	12.07	10,000	120,700	777,780	Mar 04 06:56 PM
Torley Helen	PRESIDENT AND CEO	Mar 02 '26	Sale	69.69	20,000	1,393,894	767,780	Mar 04 06:56 PM
Torley Helen	PRESIDENT AND CEO	Mar 03 '26	Sale	69.01	20,000	1,380,149	767,780	Mar 04 06:56 PM
Torley Helen	PRESIDENT AND CEO	Mar 04 '26	Sale	70.21	10,000	702,114	767,780	Mar 04 06:56 PM
Caudill Cortney	SVP, CHIEF OPERATING OFFICER	Feb 20 '26	Option Exercise	0.00	2,666	0	15,403	Feb 24 06:19 PM
Snyder Mark Howard	SVP, CHIEF LEGAL OFFICER	Feb 23 '26	Option Exercise	0.00	7,011	0	51,392	Feb 24 06:16 PM
Snyder Mark Howard	SVP, CHIEF LEGAL OFFICER	Feb 20 '26	Option Exercise	0.00	5,332	0	47,257	Feb 24 06:16 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 23 '26	Option Exercise	0.00	6,688	0	42,102	Feb 24 06:14 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 20 '26	Option Exercise	0.00	5,332	0	38,290	Feb 24 06:14 PM
Torley Helen	PRESIDENT AND CEO	Feb 23 '26	Option Exercise	0.00	22,436	0	779,884	Feb 24 06:12 PM
Torley Helen	PRESIDENT AND CEO	Feb 20 '26	Option Exercise	0.00	16,757	0	766,488	Feb 24 06:12 PM
Snyder Mark Howard	SVP, CHIEF LEGAL OFFICER	Feb 16 '26	Option Exercise	0.00	16,812	0	48,406	Feb 17 06:53 PM
LaBrosse Nicole	SVP, CHIEF FINANCIAL OFFICER	Feb 16 '26	Option Exercise	0.00	23,773	0	40,231	Feb 17 06:52 PM
Torley Helen	PRESIDENT AND CEO	Feb 16 '26	Option Exercise	0.00	89,055	0	777,336	Feb 17 06:51 PM
Torley Helen	PRESIDENT AND CEO	Feb 03 '26	Option Exercise	12.07	20,000	241,400	728,719	Feb 05 07:38 PM
Torley Helen	PRESIDENT AND CEO	Feb 04 '26	Option Exercise	12.07	20,000	241,400	728,719	Feb 05 07:38 PM
Torley Helen	PRESIDENT AND CEO	Feb 05 '26	Option Exercise	12.07	10,000	120,700	718,719	Feb 05 07:38 PM
Torley Helen	PRESIDENT AND CEO	Feb 04 '26	Sale	77.24	20,000	1,544,820	708,719	Feb 05 07:38 PM
Torley Helen	PRESIDENT AND CEO	Feb 03 '26	Sale	76.12	20,000	1,522,317	708,719	Feb 05 07:38 PM
Torley Helen	PRESIDENT AND CEO	Feb 05 '26	Sale	78.64	10,000	786,366	708,719	Feb 05 07:38 PM
Helen Torley	President, CEO, Director	Feb 03 '26	Proposed Sale	74.45	150,000	11,167,500		Feb 03 04:17 PM
Connaughton Bernadette	Director	Jan 05 '26	Sale	70.25	2,000	140,500	40,123	Jan 06 06:55 PM
Snyder Mark Howard	SVP, CHIEF LEGAL OFFICER	Jan 03 '26	Option Exercise	0.00	7,611	0	38,424	Jan 06 06:55 PM
BERNADETTE CONNAUGHTON	Director	Jan 05 '26	Proposed Sale	70.31	2,000	140,620		Jan 05 04:39 PM
Caudill Cortney	SVP, CHIEF OPERATING OFFICER	Nov 01 '25	Option Exercise	0.00	9,326	0	17,000	Dec 19 05:39 PM
Caudill Cortney	SVP, CHIEF OPERATING OFFICER	Nov 01 '25	Sale	65.19	4,263	277,905	12,737	Dec 19 05:39 PM
Connaughton Bernadette	Director	Dec 01 '25	Sale	71.60	829	59,356	42,123	Dec 01 07:50 PM
Torley Helen	PRESIDENT AND CEO	Dec 01 '25	Option Exercise	8.11	16,569	134,375	725,288	Dec 01 07:31 PM
Torley Helen	PRESIDENT AND CEO	Dec 01 '25	Sale	68.92	16,569	1,141,925	708,719	Dec 01 07:31 PM
Torley Helen	PRESIDENT AND CEO	Nov 10 '25	Option Exercise	8.11	20,000	162,200	753,719	Nov 12 06:54 PM
Torley Helen	PRESIDENT AND CEO	Nov 11 '25	Option Exercise	8.11	20,000	162,200	753,719	Nov 12 06:54 PM
Torley Helen	PRESIDENT AND CEO	Nov 12 '25	Option Exercise	8.11	20,000	162,200	753,719	Nov 12 06:54 PM
Torley Helen	PRESIDENT AND CEO	Nov 12 '25	Sale	70.55	20,000	1,410,990	733,719	Nov 12 06:54 PM
Torley Helen	PRESIDENT AND CEO	Nov 11 '25	Sale	69.13	20,000	1,382,600	733,719	Nov 12 06:54 PM
Torley Helen	PRESIDENT AND CEO	Nov 10 '25	Sale	68.72	20,000	1,374,339	733,719	Nov 12 06:54 PM
Connaughton Bernadette	Director	Nov 10 '25	Sale	68.48	2,000	136,960	42,952	Nov 12 05:58 PM

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.

M.R.C.P.Dr. Helen I. Torley M.B. Ch. B.

Executive VPMr. Mark Snyder Esq.

Senior VP & CFOMr. Darren Snellgrove

Chief Human Resources OfficerMr. Brian Sweeney

President of Drug DeliveryMr. David A. Ramsay MBA

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HALO

Halozyme Therapeutics Inc

Upgrade your Finviz experience